Saudi Food and Drug Authority launches 'Nader' program to speed up rare disease drug approvals

The Saudi Food and Drug Authority has introduced the Nader program to expedite the approval process for rare disease medications. This initiative aims to streamline the development and licensing of pharmaceutical products specifically designed to treat or prevent rare diseases, which are defined as conditions affecting fewer than five individuals out of every 10,000 in Saudi Arabia.

The Saudi Food and Drug Authority has acknowledged that such treatments are often lacking effective existing therapies or offer significant therapeutic advantages over current options.

Eligible pharmaceutical products must be in the development stage or licensed by an external regulatory body but not yet registered within the Kingdom. The Authority has pledged to provide an array of incentives and facilitations to support this program. These incentives encompass scientific and regulatory guidance, adaptable strategies for gathering scientific evidence considering the limited patient populations, and streamlined processes for factory registration and compliance with periodic safety report requirements.

The primary objective of the program is to ensure that patients suffering from rare diseases gain timely access to promising treatments. This aligns with the broader goals outlined in Saudi Vision 2030, which seeks to enhance healthcare delivery and patient outcomes across the Kingdom.